Xalatan, Xelpros, Roclanda (latanoprost) is a small molecule pharmaceutical. Latanoprost was first approved as Xalatan on 1996-06-05. It is used to treat open-angle glaucoma in the USA. It has been approved in Europe to treat ocular hypertension and open-angle glaucoma. The pharmaceutical is active against prostaglandin F2-alpha receptor. Xalatan's patents are valid until 2029-09-12 (FDA).
|Indication||ocular hypertension, open-angle glaucoma|